Setting new standards in information exchange for the pharmaceutical and biotech industry
The Chief Medical Officer Summit 2016 Announces 2 New Co-Chairs
March 14, 2016
We are delighted to announce women leadership at the 4th Annual Chief Medical Officer Summit. ShiYin Foo, MD, PhD, CMO, Cardioxyl and Catherine Wheeler, MD, CMO, SVP Clinical Development, Acetylon Pharmaceuticals are confirmed to co-chair the event on May 11-12th in Boston, MA. Drs Foo and Wheeler will provide valuable insight and leadership during the course of the Summit, as we tackle the unique challenges faced by CMOs of emerging biotechs. We are honored to have them.
The Chief Medical Officer Summit will be held at the Colonnade Hotel on May 11-12, 2016 in Boston, MA.
About ShiYin Foo, MD, PhD
Dr Foo was appointed Chief Medical Officer in 2013. She joins Cardioxyl from Novartis, where she was responsible for the establishment and execution of multiple novel programs in heart failure and the cardiorenal space, and is a named inventor on several associated patents applications. She has served as clinical and translational medicine reviewer for numerous studies spanning the full spectrum of Phase I to Phase III clinical trials. Through her experience in both industry and practice, Dr Foo has developed deep expertise in both acute and chronic heart failure. Dr Foo previously was an Assistant Physician in Medicine, Division of Cardiology at Massachusetts General Hospital in Boston, where she served as an attending physician in heart failure/transplantation. Her research focused on the effects of diet on endothelial stem cells and on novel biomarkers to identify these stem cells in vivo. She received the GSK Cardiovascular Foundation Young Investigator Award for this work. Dr Foo obtained her MD and PhD in Immunology at Stanford University and her MMSc in the Clinical Investigator Training Program at Harvard Medical School. She also holds a BA in Molecular, Cellular and Developmental Biology from Princeton University. Dr Foo was a clinical fellow in Cardiology with subspecialty training in Heart Failure/Transplantation at Massachusetts General Hospital, where she was a winner of the Roman DeSanctis Clinical Scholar Award for clinical expertise. She is board-certified in Internal Medicine and in Cardiovascular Medicine.
About Catherine Wheeler, MD
Dr Catherine Wheeler joined Acetylon in November 2010 from Roche Pharmaceuticals, Inc, (Hoffmann-La Roche) where she was Site Head, Translational Medicine, Oncology and served earlier as Head, Signal Transduction I and Ad Interim Head, Roche Oncology Clinical Development. Prior to Roche, Dr Wheeler was with AstraZeneca where she served as Vice President, Strategic Planning and Business Development, Oncology and Infection and previously in clinical development as Global Product Director Product Medical Director for the Emerging Product Team. She held multiple positions at PAREXEL International Corporation including Executive Director, Oncology Therapeutic Area Group and Medical Director. She was Clinical Director of the Bone Marrow Transplant Program at the Beth Israel Hospital in Boston, Massachusetts and was an Attending Physician and a Fellow at Beth Israel and the Dana-Farber Cancer Institute. Dr Wheeler is a graduate of Bennington College and received her MD degree with honors from the Abraham Lincoln School of Medicine at the University of Illinois. She is Board certified in internal medicine, hematology and medical oncology, was an American Cancer Society Clinical Fellowship, and serves as Clinical Associate Professor of Medicine at Harvard Medical School.